ClinicalBiostats

Clinical Trials

See the methods at work.

Statistical analyses of real clinical trials: design, endpoints, results and interpretation, organized by therapeutic area and linked to the methods behind them.

11,187 trials analyzed so far

Trials that use: Covariate adjustment

5,848 results

V-EXTRA-CVDIndependent statistical analysis of A Nurse-led Intervention to Extend the Veteran HIV Treatment Cascade for Cardiovascular Disease Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 305NCT04545489
VA CARDSIndependent statistical analysis of Coronary Artery Revascularization in Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00326196).Phase 4Results postedn = 198NCT00326196
VA-TECIndependent statistical analysis of Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01855399).Phase NAResults postedn = 290NCT01855399
VALUEIndependent statistical analysis of Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel…Phase NAResults postedn = 427NCT02750800
VATIndependent statistical analysis of Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 4Results postedn = 32NCT01750268
VC01-103Independent statistical analysis of A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1/2Results postedn = 31NCT04678557
VECTORIndependent statistical analysis of Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 636NCT01396421
VECTORIndependent statistical analysis of Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 70NCT05062759
VEGAIndependent statistical analysis of Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02396316).Phase 3Results postedn = 54NCT02396316
VELVETIndependent statistical analysis of A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor…Phase 2Results postedn = 213NCT01565083
VENTUREIndependent statistical analysis of the VENTURE phase 3 trial evaluating dupilumab in patients with severe steroid-dependent asthma, including its randomized design, oral corticosteroid reduction endpoints, ANCOVA, logistic regression, missing-data methods, and reported…Phase 3Results postedn = 210NCT02528214
VENUSIndependent statistical analysis of Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 722NCT01400776
VERITASIndependent statistical analysis of A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal…Phase 3Results postedn = 111NCT00242580
VERITASIndependent statistical analysis of Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary: primary endpoint…Phase NAResults postedn = 244NCT02636608
VERTIS CVIndependent statistical analysis of VERTIS CV (NCT01986881): a stratified Cox non-inferiority analysis of ertugliflozin versus placebo for MACE with a 1.3 hazard-ratio margin, cLDA analyses of A1C change in glycemic sub-studies, secondary…Phase 3Results postedn = 8,246NCT01986881
VIBRANTIndependent statistical analysis of Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO): primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 183NCT01521559
VICARESIndependent statistical analysis of A Study Evaluating ClariVein With a Sclerosing Agent for the Treatment of Venous Insufficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 19NCT03311269
VICTOSIndependent statistical analysis of Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 315NCT01673282
VIEW 2Complete statistical analysis of VIEW 2, the randomized phase 3 trial comparing aflibercept with ranibizumab in wet age-related macular degeneration, including non-inferiority methodology, ANCOVA, risk differences, and reported week 52 results.Phase 3Results postedn = 1,240NCT00637377
VIEW1A detailed statistical analysis of VIEW1, the randomized phase 3 trial evaluating aflibercept injection versus ranibizumab in patients with macular degeneration, including its non-inferiority design, primary visual-acuity endpoint, ANCOVA analyses, and reported…Phase 3Results postedn = 1,217NCT00509795
VIOLETIndependent statistical analysis of A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 438NCT03562156
VisipaqueIndependent statistical analysis of Comparison of Contrast Agents During CT Angiography: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01534975).Phase NAResults postedn = 513NCT01534975
Vita-ShockIndependent statistical analysis of Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02786498).Phase 2Results postedn = 102NCT02786498
VITALIndependent statistical analysis of A Study of Dog Adoption in Veterans With Posttraumatic Stress Disorder (PTSD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase EARLY_1Results postedn = 19NCT01729026
VITALITY-HFpEFIndependent statistical analysis of Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03547583).Phase 2Results postedn = 789NCT03547583
VitalpsIndependent statistical analysis of Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1/2Results postedn = 23NCT02104505
VIVID-1Independent statistical analysis of A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03926130).Phase 3Results postedn = 1,158NCT03926130
VR-THEIAIndependent statistical analysis of Impact of Virtual Reality on Pre-procedural anxieTy Prior to Heart cathEterIzAtion - VR-THEIA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 180NCT03662607
VRI01Independent statistical analysis of Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 92NCT02038842
VRPE ExtensionIndependent statistical analysis of Comparing Virtual Reality Exposure Therapy to Prolonged Exposure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01459705).Phase NAResults postedn = 162NCT01459705
Wait and SeeIndependent statistical analysis of Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 4Results postedn = 1,179NCT01202279
WalkITIndependent statistical analysis of A Walking Intervention Through Text Messaging: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02053259).Phase NAResults postedn = 96NCT02053259
WARCEFComplete statistical analysis of the WARCEF trial, comparing warfarin with aspirin in patients with reduced cardiac ejection fraction, including trial design, time-to-event endpoints, Cox and Poisson regression, reported results, safety, and statistical…Phase 3Results postedn = 2,305NCT00041938
WAVEIndependent statistical analysis of Durvalumab Long-Term Safety and Efficacy Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04078152).Phase 4Results postedn = 163NCT04078152
WEARIT-FRIndependent statistical analysis of LifeVest Safety and Efficacy in Real Life Settings in France: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03319160).Phase NAResults postedn = 1,164NCT03319160
WH-PACTIndependent statistical analysis of Implementation of Women's Health Patient Aligned Care Teams: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02039856).Phase NAResults postedn = 3,900NCT02039856
WHISPERIndependent statistical analysis of Effectiveness of the Precision Spinal Cord Stimulator System at Sub-Perception Amplitude: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 229NCT02314000
WILLOW TREEIndependent statistical analysis of The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin: primary endpoint results, effect estimate with…Phase 4Results postedn = 72NCT03869268
WRAPIndependent statistical analysis of Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 63NCT03799341
YeapleIndependent statistical analysis of Clinical Efficacy of a Toothpaste on Hypersensitivity Reduction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01040169).Phase NAResults postedn = 79NCT01040169
YELLOW IIIIndependent statistical analysis of Effect of Evolocumab on Coronary Plaque Characteristics: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04710368).Phase 4Results postedn = 137NCT04710368
YES-PIndependent statistical analysis of Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 36NCT01887717
YOGAMAT-IIIndependent statistical analysis of Optimization and Multi-Site Feasibility of Yoga for Chronic Pain in People in YOGAMAT-II - Phase II: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 192NCT04641221
ZEAL UNLOCKIndependent statistical analysis of A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 73NCT06269484
ZENITHIndependent statistical analysis of A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH): primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 173NCT04896008
ZEUSIndependent statistical analysis of Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2/3Results postedn = 465NCT02753946
ZODIACIndependent statistical analysis of OptimiZation Of Lipid Lowering Therapies Using a Decision Support System In Patients With Acute Coronary Syndrome.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 1,139NCT05844566
ZoMARSIndependent statistical analysis of Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 48NCT01348269